Nanomedicinal strategies to treat multidrug-resistant tumors: current progress

Nanomedicine (Lond). 2010 Jun;5(4):597-615. doi: 10.2217/nnm.10.35.


Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. P-glycoprotein is an important and the best-known membrane transporter involved in MDR. Several strategies have been used to address MDR, especially P-glycoprotein-mediated drug resistance in tumors. However, clinical success has been limited, largely due to issues regarding lack of efficacy and/or safety. Nanoparticles have shown the ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-glycoprotein and the observed improved anticancer efficacy suggests that nanomedicinal strategies provide a new opportunity to overcome MDR. This article focuses on nanotechnology-based formulations and current nanomedicine approaches to address MDR in tumors and discusses the proposed mechanisms of action.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Drug Resistance, Multiple
  • Drug Resistance, Neoplasm
  • Humans
  • Nanomedicine*
  • Neoplasms / drug therapy*